Research on Correlation Between Psychological Factors, Mast Cells, and PAR-2 Signal Pathway in Irritable Bowel syndrome

References

• Sperber AD, Dumitrascu D, Fukudo S, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome foundation working team literature review. Gut. 2017;66(6):1075–1082. doi:10.1136/gutjnl-2015-311240
   PubMed Web of Science ®Google Scholar
• Lacy BE, Mearin F, Chang L, et al. Bowel disorders. J Gastroenterol. 2016;150(6):1393–1407. doi:10.1053/j.gastro.2016.02.031
   Google Scholar
• Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313(9):949–958. doi:10.1001/jama.2015.0954
   PubMed Web of Science ®Google Scholar
• Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut. 2000;46:78–82. doi:10.1136/gut.46.1.78
   PubMed Web of Science ®Google Scholar
• Bolino CM, Bercik P. Pathogenic factors involved in the development of irritable bowel syndrome: focus on a microbial role. Infect Dis Clin N Am. 2010;24(4):961–975. doi:10.1016/j.idc.2010.07.005
   PubMed Web of Science ®Google Scholar
• Imperatore N, Tortora R, Morisco F, Caporaso N. Gut microbiota and functional diseases of the gastrointestinal tract. Minerva Gastroenterol Dietol. 2017;63:355–372. doi:10.23736/S1121-421X.16.02336-9
   PubMed Web of Science ®Google Scholar
• Sibelli A, Chalder T, Everitt H, et al. Positive and negative affect mediate the bidirectional relationship between emotional processing and symptom severity and impact in irritable bowel syndrome. J Psychosom Res. 2018;105:1–13. doi:10.1016/j.jpsychores.2017.11.016
   PubMed Web of Science ®Google Scholar
• Radziwon CD, Lackner JM. Cognitive behavioral therapy for ibs: how useful, how often, and how does it work? Curr Gastroenterol Rep. 2017;19(10):49. doi:10.1007/s11894-017-0590-9
   PubMedGoogle Scholar
• Wang Y, Chen F, Shi H, et al. Extrinsic ghrelin in the paraventricular nucleus increases small intestinal motility in rats by activating central growth hormone secretagogue and enteric cholinergic receptors. Peptides. 2015;74:43–49. doi:10.1016/j.peptides.2015.09.009
   PubMed Web of Science ®Google Scholar
• Chao G-Q, Zhang S. A meta-analysis of the therapeutic effects of amitriptyline for treating irritable bowel syndrome. Intern Med. 2013;52(4):419–424. doi:10.2169/internalmedicine.52.9147
   PubMed Web of Science ®Google Scholar
• Ford AC, Quigley EM, Lacy BE, et al. Effect of antidepressants and psychologicaltherapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2014;109:1350–1365. doi:10.1038/ajg.2014.148
   PubMed Web of Science ®Google Scholar
• Xie JF, Shao YF, Wang HL, et al. Neuropeptide S Counteracts Paradoxical Sleep Deprivation-Induced Anxiety-Like Behavior and Sleep Disturbances. Front Cell Neurosci. 2018;12:64. doi:10.3389/fncel.2018.00064
   PubMed Web of Science ®Google Scholar
• Thomasson J, Canini F, Poly-Thomasson B, et al. Neuropeptide S overcomes short term memory deficit induced by sleep restriction by increasing prefrontal cortex activity. Eur Neuropsychopharmacol. 2017;27(12):1308–1318. doi:10.1016/j.euroneuro.2017.08.431
   PubMed Web of Science ®Google Scholar
• Duarte-Neves J, Pereira de Almeida L, Cavadas C. Neuropeptide Y (NPY) as a therapeutic target for neurological diseases. Neurobiol Dis. 2016;95:210–224.
   PubMed Web of Science ®Google Scholar
• Quirk S, Hopkins MM, Bureau H, et al. Mutational analysis of neuropeptide y reveals unusual thermal stability linked to higher-order self-association. ACS Omega. 2018;3(2):2141–2154. doi:10.1021/acsomega.7b01949
   PubMed Web of Science ®Google Scholar
• Oikonomopoulou K, Hansen KK, Saifeddine M, et al. Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs). Biol Chem. 2006;387:817–824. doi:10.1515/BC.2006.104
   PubMed Web of Science ®Google Scholar
• Cenac N, Coelho AM, Nguyen C, et al. Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol. 2002;161:1903–1915. doi:10.1016/S0002-9440(10)64466-5
   PubMed Web of Science ®Google Scholar
• Grabauskas G, Wu X, Gao J, et al. Prostaglandin E2, produced by mast cells in colon tissues from patients with irritable bowel syndrome, contributes to visceral hypersensitivity in mice. Gastroenterology. 2020;158(8):2195–2207. doi:10.1053/j.gastro.2020.02.022
   PubMed Web of Science ®Google Scholar
• Guilarte M, Vicario M, Martínez C, et al. Peripheral Corticotropin-Releasing Factor Triggers Jejunal Mast Cell Activation and Abdominal Pain in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. Am J Gastroenterol. 2020;115(12):2047–2059. doi:10.14309/ajg.0000000000000789
   PubMed Web of Science ®Google Scholar
• Leon A, Ceauu Z, Ceauu M, et al. Mast cells and dendritic cells in basal cell carcinoma. Revue Roumaine De Morphologie Et Embryologie. 2009;50:85–90.
   Google Scholar
• Humphreys TR, Monteiro MR, Murphy GF. Mast Cells and Dendritic Cells in Basal Cell Carcinoma Stroma. Dermatologic Surgery. 2010;26:200–204. doi:10.1046/j.1524-4725.2000.09207.x
   Google Scholar
• Liu DR, Xu XJ, Yao SK. Increased intestinal mucosal leptin levels in patients with diarrhea-predominant irritable bowel syndrome. World J Gastroenterol. 2018;24:46–57. doi:10.3748/wjg.v24.i1.46
   PubMed Web of Science ®Google Scholar
• Shah K, Maghsoudlou P. Enzyme-linked immunosorbent assay (ELISA): the basics. Br J Hosp Med. 2016;77(7):C98–C101. doi:10.12968/hmed.2016.77.7.C98
   PubMed Web of Science ®Google Scholar
• Liu G, Wang Y, Wang C, et al. Clinical efficacy and safety of apatinib as maintenance treatment in patients with advanced esophageal squamous cell carcinoma. Expert Rev Clin Pharmacol. 2020;13(12):1423–1430. doi:10.1080/17512433.2020.1844004
   PubMed Web of Science ®Google Scholar
• Gopi K. Prevalence of irritable bowel syndrome in college students and assoctation with anxiety, depression and food map diet. J Mazandaran Univ Med Sci. 2015;2:4949–4957.
   Google Scholar
• Elyse T, Brian Q, Hashem E, et al. Medical comorbidity and distress in patients with irritable bowel syndrome: the moderating role of age. J Psychosom Res. 2016;88:48–53. doi:10.1016/j.jpsychores.2016.07.006
   PubMed Web of Science ®Google Scholar
• Kask A, Nguyen HP, Pabst R, et al. Neuropeptide Y Y1 receptor-mediated anxiolysis in the dorsocaudal lateral septum: functional antagonism of corticotropin-releasing hormone-induced anxiety. Neuroscience. 2001;104(3):799–806. doi:10.1016/S0306-4522(01)00116-6
   PubMed Web of Science ®Google Scholar
• Rizzi A, Vergura R, Marzola G, et al. Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in mice. Br J Pharmacol. 2008;154(2):471–479. doi:10.1038/bjp.2008.96
   PubMed Web of Science ®Google Scholar
• Zhang L, Riepler SJ, Turner N, et al. Y2 and Y4 receptor signaling synergistically act on energy expenditure and physical activity. Am J Physiol Regul Integr Comp Physiol. 2010;299(6):1618–1628. doi:10.1152/ajpregu.00345.2010
   Web of Science ®Google Scholar
• Han RW, Chang M, Peng YL, et al. Central Neuropeptide S inhibits distal colonic transit through activation of central Neuropeptide S receptor in mice. Peptides. 2009;30:1313–1317. doi:10.1016/j.peptides.2009.03.012
   PubMed Web of Science ®Google Scholar
• Ann M. Rasmusson. The gut peptide neuropeptide Y and post-traumatic stress disorder. Curr Opin Endocrinol Diabetes Obes. 2017;24:3–8. doi:10.1097/MED.0000000000000301
   PubMedGoogle Scholar
• Tough IR, Forbes S, Tolhurst R, et al. Endogenous peptide YY and neuropeptide Y inhibit colonic ion transport, contractility and transit differentially via Y 1 and Y 2 receptors. Br J Pharmacol. 2011;164:471–484. doi:10.1111/j.1476-5381.2011.01401.x
   PubMed Web of Science ®Google Scholar
• Forbes SC, Cox HM, Peptide YY. Neuropeptide Y and corticotrophin-releasing factor modulate gastrointestinal motility and food intake during acute stress. Neurogastroenterol Motil. 2014;26:1605–1614. doi:10.1111/nmo.12428
   PubMed Web of Science ®Google Scholar
• McCoy KL, Traynelis SF, Hepler JR. PAR1 and PAR2 couple to overlapping and distinct sets of G proteins and linked signaling pathways to differentially regulate cell physiology. Mol Pharmacol. 2010;77(6):1005–1015. doi:10.1124/mol.109.062018
   PubMed Web of Science ®Google Scholar
• Lee KN, Lee OY. The role of mast cells in irritable bowel syndrome. Gastroenterol Res Pract. 2016;2016:2031480. doi:10.1155/2016/2031480
   PubMed Web of Science ®Google Scholar
• Bednarska O, Walter SA, Casado-Bedmar M, et al. Vasoactive intestinal polypeptide and mast cells regulate increased passage of colonic bacteria in patients with irritable bowel syndrome. J Gastroenterol. 2017;153(4):948–960. doi:10.1053/j.gastro.2017.06.051
   Google Scholar
• Reed DE, Barajas-Lopez C, Cottrell G, et al. Mast cell tryptase and proteinase-activated receptor 2 induce hyperexcitability of guineapig submucosal neurons. J Physiol. 2003;547:531–542. doi:10.1113/jphysiol.2002.032011
   PubMed Web of Science ®Google Scholar
• Cenac N, Coelho AM, Nguyen C, et al. Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol. 2002;161:1903–1915.
   PubMed Web of Science ®Google Scholar
• Cenac N, Andrews CN, Holzhausen M, et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest. 2007;117(3):636–647. doi:10.1172/JCI29255
   PubMed Web of Science ®Google Scholar